Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its ...

Respiratorius AB research and ratings by Barron's. View HF00 revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...

First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...

The acquisition brings together the gold standard for continuous ambulatory cough monitoring and lung sound analysis ...

Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...

The first one was that several participants did not know the correct inhaler regimen that they were actively prescribed at ...

Peer-reviewed study confirming strong predictive performance of patient-specific lung digital twins, validated against ...

Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...

BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and ethionamide), an innovative drug combination that overcomes ...

Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior ...

Avalyn Pharma is eyeing an IPO as the biotech seeks more funds to take its inhaled versions of approved drugs for lung ...